Expertise in
54
conditions

Dr. Samy K. Metyas

Rheumatology
500 W San Bernardino Rd, 
Covina, CA 
Accepting New Patients
31 Years of Experience
Referral may be required
Before you request
Expertise in
54
conditions
500 W San Bernardino Rd, 
Covina, CA 

Overview

Samy Metyas is a Rheumatologist practicing medicine in Covina, California. He has been practicing medicine for over 31 years.

Dr. Metyas is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Fibromyalgia, Rheumatoid Arthritis (RA), Osteoporosis, and Postmenopausal Osteoporosis.

Dr. Metyas is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 16 clinical trials. Dr. Metyas is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

LAC/USC Medical Center , Rheumatology , 2001 - 2003

Hospital Affiliations

San Antonio Regional Hospital
Emanate Health Foothill Presbyterian Hospital
Pomona Valley Hospital Medical Center
Casa Colina Hospital
Emanate Health Inter-Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Metyas, Samy, M.d., Inc.
500 W San Bernardino Rd, Covina, CA 91722

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Device, Drug
Study Drug: Conventional Synthetic DMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Drug
Study Drugs: Sodium Hyaluronate, Triamcinolone Hexacetonide
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

Diet and Lifestyle Modifications for Fibromyalgia.
Diet and Lifestyle Modifications for Fibromyalgia.
Journal: Current rheumatology reviews
Published: August 16, 2023
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (27.1 miles away)
Languages Spoken:
English
See accepted insurances

Daniel Wallace is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Wallace is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Referral may be required
Before you request

Daniel Furst MD A Professional Corp.

575 E Hardy St Ste 321, 
Inglewood, CA 
 (27.5 miles away)
818-561-9989
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Furst is a Rheumatologist practicing medicine in Inglewood, California. Dr. Furst is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Rheumatoid Arthritis (RA), and Arthritis. Dr. Furst is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
2020 Santa Monica Boulevard, Suite 540, 
Santa Monica, CA 
 (33.5 miles away)
310-582-6350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanaz Kermani is a Rheumatologist practicing medicine in Santa Monica, California. Dr. Kermani is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, and Takayasu Arteritis. Dr. Kermani is currently accepting new patients.

Frequently Asked Questions about Dr. Samy K. Metyas

How do I make an appointment with Dr. Samy K. Metyas?

You can book an appointment with Dr. Samy K. Metyas by calling their office at 626-966-1909. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samy K. Metyas a top-rated expert for Fibromyalgia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samy K. Metyas is classified as an Elite expert for Fibromyalgia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samy K. Metyas specialize in?

While Dr. Samy K. Metyas is a Rheumatology, they have specific expertise in Fibromyalgia, Rheumatoid Arthritis (RA), and Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Samy K. Metyas participate in research or clinical trials?

Yes. Dr. Samy K. Metyas has published 11 articles and abstracts on conditions like Fibromyalgia. You can view a list of Dr. Samy K. Metyas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samy K. Metyas accept my insurance?

Dr. Samy K. Metyas accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 626-966-1909 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Metyas's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 35 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile